CDMO - ペレグリン・ファ―マシュ―ティカルズ （Avid Bioservices Inc.）

Avid Bioservices manufactures monoclonal antibodies and various biologics for biotech and pharmaceutical companies. The company hit record revenues in fiscal Q3 2023, up 21% YoY achieving non-GAAP profitability. Avid is adding manufacturing capacity with a new facility planned to open in Spring 2023. Avid Bioservices trade at 8X forward earnings and has a 7.59% short […]

The bio-manufacturer''s ongoing expansion efforts are a hit with investors.

Avid Bioservices (CDMO) gained ~34% on Tuesday morning after the contract manufacturer reported better-than-expected financials for Q3 FY23, prompting KeyBanc to upgrade it.

PaxMedica (PXMD) +36%. Avid Bioservices (CDMO) +25%. Rapt Therapeutics, (RAPT) -23%. Unicycive Therapeutics (UNCY) -16%.

https://www.investing.com/news/pro/keybanc-upgrades-avid-bioservices-to-overweight-432SI-3029586

According to Benzinga Pro data Avid Bioservices (NASDAQ: CDMO ) posted a 98.65% decrease in earnings from Q4. Sales, however, increased by 17.5% over the previous quarter to $36.69 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Avid Bioservices is not utilizing their capital as effectively as possible. Avid Bioservices reached earnings of $115.60 million and sales of $31.23 million in Q4. What Is Return On Invested Capital? Earnings data without context is not clear and can difficult to base trading decisions on. Return on Invested Capital (ROIC) helps to filter signal from noise by measuring yearly … Full story available on Benzinga.com

Avid Bioservices Inc. (NASDAQ:CDMO) price on Friday, September 09, rose 6.45% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $18.33. A look at the stock’s price movement, the close in the last trading session was $17.22, moving within a range at $17.35 and $18.40. The beta value … Analysts Predicting A Spike In Avid Bioservices Inc. (NASDAQ: CDMO)? Read More »

TUSTIN, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the Morgan Stanley 20 th Annual Global Healthcare Conference. Nick Green, president and chief executive officer of Avid Bioservices, will be the featured speaker in a fireside chat at the conference, which will take place September 12-14, 2022, in New York City.

Avid Bioservices, Inc. (NASDAQ:NASDAQ:CDMO) Q1 2023 Earnings Conference Call September 6, 2022 16:30 ET Company Participants Tim Brons - Investor Relations Nick Green - President and Chief…

Avid Bioservices Earnings Miss, Revenue Beats In Q1

Avid Bioservices press release (CDMO): Q3 GAAP EPS of $0.04 in-line.Revenue of $31.51M (+44.5% Y/Y) beats by $6.2M.Guidance: The company is reiterating revenue guidance for fiscal…

Artisan Partners, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ fourth quarter 2021 investor letter – a copy of which can be downloaded here.